EP0613367B1 - Dermatologische und kosmetische Zusammensetzung - Google Patents

Dermatologische und kosmetische Zusammensetzung Download PDF

Info

Publication number
EP0613367B1
EP0613367B1 EP92923386A EP92923386A EP0613367B1 EP 0613367 B1 EP0613367 B1 EP 0613367B1 EP 92923386 A EP92923386 A EP 92923386A EP 92923386 A EP92923386 A EP 92923386A EP 0613367 B1 EP0613367 B1 EP 0613367B1
Authority
EP
European Patent Office
Prior art keywords
compositions according
active ingredients
agents
emulsifying
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP92923386A
Other languages
English (en)
French (fr)
Other versions
EP0613367A1 (de
Inventor
Luciano Fontanelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abiogen Pharma SRL
Original Assignee
Istituto Gentili SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Istituto Gentili SpA filed Critical Istituto Gentili SpA
Publication of EP0613367A1 publication Critical patent/EP0613367A1/de
Application granted granted Critical
Publication of EP0613367B1 publication Critical patent/EP0613367B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/39—Derivatives containing from 2 to 10 oxyalkylene groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to dermatological and cosmetic compositions and particularly to compositions having antiageing activity; said compositions are also useful in the treatment of burns, wounds and are characterized by a high stability such as to make them also suitable for the stabilization of active ingredients.
  • the British Patent Application GB-A-2 143 841 deals with the stability problem of thickened aqueous surfactant compositions for use as shaving creams and liquid soap formulations.
  • Skin is formed by cells whose state affects the external appearance of epidermis. Skin ageing derives from a slowing of the derm functions, particularly nutrition, respiration, hydration, regeneration and cutaneous tissues protection. Skin ageing is a natural phenomenon whose causes are of different origin and can be more or less fast for each person. Generally, the function slowing of certain cells, whose role is very important in maintaining the integrity of derm structure, begins around one's thirties. This phenomenon may begin at a more or less early age, due to many factors, such as genetic set, general health state, each individual's peculiar way of life.
  • the object of the present invention are dermatological and cosmetic compositions having antiageing activity and having high stability, also in the presence of active ingredients of various kind.
  • compositions according to the invention consist of: 1) emulsifying and self-emulsifying agents, having o/w activity formed by a mixture containing (as % w/w) 1') polyethylene glycol mono- or distearate 0.5-5.0 % 2') polyglycol esters of saturated or unsaturated C14-C20 fatty acids 1.0-10.0 % 3') cetyl alcohol and optionally other higher alcohols, comprising free or esterified sterols 1.0-16.0 % 2) sodium versenate and antioxidant agents 0.1-5.0 % 3) anti-mould and bacteriostatic agents 0.05-0.1 % 4) active ingredients 1-30 % 5) purified water F.U. q.s. to 100 %
  • Polyethylene glycols having various molecular weight, for example ranging from 200 to 10,000, preferably from 400 to 2,000, more preferably 1,000, can be used. Polyethylene glycol 1,000 monostearate is particularly preferred.
  • the antioxidant agents are selected from the group consisting of:
  • anti-mould and/or bacteriostatic agents are methyl or propyl p-oxybenzoates.
  • the active ingredients preferably have derm reconstituting activity.
  • active ingredients which can be used alone or combined each other, are collagen, in the several forms thereof, esurosamine, elastin, amino acids, peptides, mucopolysaccharides.
  • compositions of the invention are characterized by a remarkable eudermicity, therefore, they act in an extraordinarily favourable extent on skin stretching and smoothness (anti-wrinkle effect), translucency, on tissue stiffening, turgidity and elasticity, on the reduction of irregular fat accumulation in subcutaneous connective ("cellulitis').
  • skin irritations on children due to wet linens or sweat, on feet irritations due to maceration, on sun-induced irritations.
  • compositions of the invention also carry out a surprising dermatological activity on burns, crural ulcer, wound healings, bedsores, accelerating their recovery.
  • compositions with a formulation excluding the active ingredients of the above point 4, act as stabilizing carriers towards several active ingredients, such as vitamins, hormones, antibiotics. Accordingly, said compositions are useful for the preparation of pharmaceutical compositions containing active ingredients, which are subject to degradation due to environmental conditions (temperature, humidity, oxidants, etc.).
  • compositions of the invention maintain the titre of the active ingredients therein enclosed within the limits fixed at room temperature; particularly some vitamins showed a titre loss not higher then 10% within two years.
  • compositions of the invention are prepared according to the techniques which are well-known in dermatology and cosmetics, said compositions may be in the form of creams, lotions, milks, ointments, oils, ampoules, masks, gels, pads, sprays.
  • both creams and milks can be prepared with the same components.
  • Elastin cream Elastin (anhydrous) 1-2 g Linol-linoleic acid 1.25 g Cetyl alcohol 12.00 g Polyethylene glycol 1,000 monostearate 2.25 g Polyglycol esters of saturated or unsaturated C14-C20 fatty acids 0.375-0.75 g Free and esterified sterols 0.75 g Methyl p-oxybenzoate 0.13 g Propyl p-oxybenzoate 0.07 g Propyl gallate 0.30 g Versenic acid sodium salt 0.05 g Hamamelis water 20.50 g Propylene glycol 5.25 g Purified water 55.975-54.600 g Rose essence 0.20 g.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Birds (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (7)

  1. Dermatologische und kosmetische Zusammensetzungen, bestehend aus: 1) emulgierenden und selbstemulgierenden Mittel, die eine O/W-Aktivität aufweisen, die durch ein Gemisch gebildet werden, das enthält (als % Gew./Gew.) 1') Polyethylenglycolmono- oder -distearat 0,5 - 5,0 % 2') Polyglycolester von gesättigten oder ungesättigten C₁₄-C₂₀-Fettsäuren 1,0 -10,0 % 3') Cetylalcohol und wahlweise andere höhere Alkohole, die freie oder veresterte Sterole umfassen 1,0 -16,0 % 2) Natriumversenat und Antioxidationsmittel 0,1 - 5,0 % 3) Mittel gegen Schimmel und bakteriostatische Mittel 0,05- 0,1 % 4) Wirkstoffe 1 - 30 % 5) gereinigtes Wasser F.U. q.s. auf 100 %
  2. Zusammensetzungen nach Anspruch 1, in denen die Antioxidationsmittel mehrfach ungesättigte Fettsäuren, die zur Vitamin F-Gruppe gehören, und Tocopherolderivate sind und die Wirkstoffe ausgewählt sind aus der Gruppe bestehend aus Collagen in seinen verschiedenen Formen, Esurosamin, Elastin, Aminosäuren, Peptide, Mucopolysaccharide.
  3. Zusammensetzungen nach Anspruch 1, in denen die Wirkstoffe ausgewählt sind aus der Gruppe bestehend aus Vitaminen, Hormonen, Antibiotika.
  4. Zusammensetzungen nach Ansprüchen 1 und 2, in denen eine Komponente des emulgierenden Mittels Polyethylenglycol-1000-Monostearat ist.
  5. Zusammensetzungen nach Ansprüchen 1 - 3, in denen das Tocopherolderivat Tocopherylacetat ist.
  6. Zusammensetzungen nach Ansprüchen 1 - 4, in denen das Mittel gegen Schimmel Methyl- oder Propyl-p-oxybenzoat ist.
  7. Zusammensetzungen nach Ansprüchen 1 - 5 in Form von Milch, Lotionen, Cremes, Salben, Ölen, Ampullen, Masken, Gelen, Pads, Sprays.
EP92923386A 1991-11-22 1992-11-12 Dermatologische und kosmetische Zusammensetzung Expired - Lifetime EP0613367B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITMI913127A IT1252061B (it) 1991-11-22 1991-11-22 Composizioni per uso dermatologico e cosmetico
ITMI913127 1991-11-22
PCT/EP1992/002597 WO1993009760A2 (en) 1991-11-22 1992-11-12 Dermatological and cosmetic compositions

Publications (2)

Publication Number Publication Date
EP0613367A1 EP0613367A1 (de) 1994-09-07
EP0613367B1 true EP0613367B1 (de) 1995-11-02

Family

ID=11361168

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92923386A Expired - Lifetime EP0613367B1 (de) 1991-11-22 1992-11-12 Dermatologische und kosmetische Zusammensetzung

Country Status (17)

Country Link
US (1) US5575994A (de)
EP (1) EP0613367B1 (de)
JP (1) JPH07501066A (de)
KR (1) KR100218132B1 (de)
AT (1) ATE129633T1 (de)
AU (1) AU660738B2 (de)
BG (1) BG61382B1 (de)
CA (1) CA2123910A1 (de)
CZ (1) CZ282574B6 (de)
DE (1) DE69205839T2 (de)
DK (1) DK0613367T3 (de)
HU (1) HU214945B (de)
IT (1) IT1252061B (de)
NO (1) NO303564B1 (de)
RU (1) RU2126243C1 (de)
SK (1) SK279386B6 (de)
WO (1) WO1993009760A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19501288A1 (de) * 1995-01-18 1996-07-25 Beiersdorf Ag Fettsäurederivate enthaltende Lotionen
WO1996031192A1 (de) * 1995-04-07 1996-10-10 Kuyus-Stiftung Kosmetische zusammensetzung zur behandlung von cellulite
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
ITMI20021204A1 (it) * 2002-06-04 2003-12-04 Abiogen Pharma Spa Composizioni contenenti dolicolo per uso dermatologico e cosmetico
RU2224534C1 (ru) * 2002-09-24 2004-02-27 Общество с ограниченной ответственностью Парфюмерно-косметическая фирма Интеркосметика Биологически активное вещество
JP4247758B2 (ja) * 2003-02-18 2009-04-02 日本光電工業株式会社 炭酸ガス測定センサ
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
JP4523388B2 (ja) * 2004-11-19 2010-08-11 日本メナード化粧品株式会社 コラーゲン合成促進剤及び皮膚外用剤
IT1393422B1 (it) * 2009-03-23 2012-04-20 Nicoletti Composizione cosmetica contenente collagene ed elastina
CN102481275B (zh) 2009-06-24 2014-07-23 战略科学技术有限公司 含有布洛芬的表面组合物
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9463158B2 (en) 2009-06-24 2016-10-11 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US20110082247A1 (en) * 2009-10-06 2011-04-07 Amcol International Corp. Viscosity modified alcohols
US9289495B2 (en) 2010-12-29 2016-03-22 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1168949A (en) * 1979-08-13 1984-06-12 William G. Gorman Cleansing compositions
EP0049354A3 (de) * 1980-09-08 1983-02-23 Sterling Drug Inc. Mischung zur therapeutischen, antiviralen Verwendung sowie Artikel und Packungen, die diese Mischung enthalten
US4474763A (en) * 1982-07-07 1984-10-02 Lubowe Irwin I Skin preparation
LU84485A1 (fr) * 1982-11-22 1984-06-13 Oreal Nouvelle composition anti-acneique a base de peroxyde de benzoyle et d'au moins un autre principe actif
DE3304896A1 (de) * 1983-02-12 1983-08-04 Inge Rehberg Herstellung einer lagerbestaendigen oel-in-wasser-emulsion fuer kosmetische zwecke
GB2143841A (en) * 1983-07-26 1985-02-20 Wilkinson Sword Ltd Soap compositions
US4695452A (en) * 1984-10-10 1987-09-22 Gannis Peter M Cosmetic stick
US4883792A (en) * 1989-01-17 1989-11-28 Peter Timmins Steroid cream formulation
IL95393A0 (en) * 1989-08-18 1991-06-30 John Morris Co Odor-masked and stabilized compositions for treating keratinous tissue,skin conditions,and promoting wound healing
FR2688006A1 (fr) * 1992-02-27 1993-09-03 Oreal Dispersion d'un hydrocarbure fluore dans une solution aqueuse d'un polymere filmogene et son utilisation pour la formation de films composites notamment en cosmetique.
EP0610511B2 (de) * 1992-07-13 2007-08-01 Shiseido Company, Ltd. Zusammensetzung für dermatologische zubereitung

Also Published As

Publication number Publication date
HU9401533D0 (en) 1994-09-28
DK0613367T3 (da) 1996-02-26
NO941855L (no) 1994-05-18
ATE129633T1 (de) 1995-11-15
JPH07501066A (ja) 1995-02-02
WO1993009760A2 (en) 1993-05-27
EP0613367A1 (de) 1994-09-07
BG61382B1 (en) 1997-07-31
CA2123910A1 (en) 1993-05-27
CZ282574B6 (cs) 1997-08-13
ITMI913127A0 (it) 1991-11-22
RU2126243C1 (ru) 1999-02-20
US5575994A (en) 1996-11-19
SK279386B6 (sk) 1998-10-07
IT1252061B (it) 1995-05-29
ITMI913127A1 (it) 1993-05-22
AU2929692A (en) 1993-06-15
NO941855D0 (no) 1994-05-18
DE69205839T2 (de) 1996-04-04
DE69205839D1 (de) 1995-12-07
HU214945B (hu) 1998-08-28
CZ121694A3 (en) 1994-11-16
AU660738B2 (en) 1995-07-06
NO303564B1 (no) 1998-08-03
BG98762A (bg) 1995-05-31
HUT67861A (en) 1995-05-29
WO1993009760A3 (en) 1993-07-08
KR100218132B1 (ko) 1999-09-01
SK58394A3 (en) 1995-01-12

Similar Documents

Publication Publication Date Title
EP0613367B1 (de) Dermatologische und kosmetische Zusammensetzung
US6932963B2 (en) Treatment of skin wounds using polyenylphosphatidylcholine and alkanolamines
US6147121A (en) Skin toning by stimulating collagen synthesis/proliferation of dermal fibroblasts
ES2247728T3 (es) Tratamiento de tejido cicatricial utilizando acido lipoico.
JP2003081737A (ja) レチノールを３重に安定化した化粧料
KR100681480B1 (ko) 알칸올아민을 이용하는 모발 및 네일의 치료방법
US5804574A (en) Vitamin D3 analogs useful for reversing the photodamage in sun-exposed skin
EP1219288A2 (de) Zusammensetzung zur Hautbehandlung
KR20000053859A (ko) 자연산 상황버섯 추출물을 함유하는 발모제 조성물 및이의 제조방법
EP0344708B1 (de) Präparat zum äusserlichen Gebrauch auf der Haut
KR20240163854A (ko) 병풀추출물을 포함하는 화장품 조성물 및 이를 이용한 스킨패드
KR102337667B1 (ko) 피부 보습용 화장료 조성물 및 이의 제조방법
KR100433373B1 (ko) 사람의 표피성장인자를 포함하는 화장료 조성물
CN115120518B (zh) 外用添加剂及其应用、皮肤外用制品
GB2341317A (en) A topical preparation for the promotion of hair growth or regrowth containing an absorption promoting agent and/or a blood thining agent
KR20180096094A (ko) 코스모스 추출물을 포함하는 피부주름 개선용 조성물
KR20010025824A (ko) 여드름 피부용 화장료 조성물
KR20050078081A (ko) Ｓｃｍ을 함유한 피부 보습용 화장료 조성물
KR20110040768A (ko) 인간 프로락틴의 용도
KR20130016888A (ko) 빙산수를 함유하는 피부 보습용 화장료 조성물

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19940517

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19950228

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 19951102

Ref country code: ES

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19951102

REF Corresponds to:

Ref document number: 129633

Country of ref document: AT

Date of ref document: 19951115

Kind code of ref document: T

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: 65944

REF Corresponds to:

Ref document number: 69205839

Country of ref document: DE

Date of ref document: 19951207

ET Fr: translation filed
ITF It: translation for a ep patent filed
REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: HUG INTERLIZENZ AG

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 19981028

Year of fee payment: 7

REG Reference to a national code

Ref country code: CH

Ref legal event code: PUE

Owner name: ISTITUTO GENTILI S.P.A. TRANSFER- ABIOGEN PHARMA S

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

NLS Nl: assignments of ep-patents

Owner name: ABIOGEN PHARMA S.R.L.

REG Reference to a national code

Ref country code: GB

Ref legal event code: 732E

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19991112

REG Reference to a national code

Ref country code: FR

Ref legal event code: TP

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20001017

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 20001020

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 20001107

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20001108

Year of fee payment: 9

Ref country code: GB

Payment date: 20001108

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20001113

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20001114

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20001127

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20001130

Year of fee payment: 9

Ref country code: NL

Payment date: 20001130

Year of fee payment: 9

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20010116

Year of fee payment: 9

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011112

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011112

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011112

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011112

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011112

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011113

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011130

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011130

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20011130

REG Reference to a national code

Ref country code: GB

Ref legal event code: IF02

BERE Be: lapsed

Owner name: ABIOGEN PHARMA S.R.L.

Effective date: 20011130

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020601

EUG Se: european patent has lapsed

Ref document number: 92923386.4

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020702

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20020730

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20020601

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20051112